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Abstract
Epidermal growth factor receptor (EGFR) signaling is fundamentally important for tissue
homeostasis through EGFR/ligand interactions that stimulate numerous signal transduction
pathways. Aberrant EGFR signaling has been reported in inflammatory and malignant diseases but
thus far no primary inherited defects in EGFR have been recorded. Using whole-exome
sequencing, we identified a homozygous loss-of-function missense mutation in EGFR (c.
1283G>A; p.Gly428Asp) in a male infant with life-long inflammation affecting the skin, bowel
and lungs. During the first year of life, his skin showed erosions, dry scale, and alopecia.
Subsequently, there were numerous papules and pustules – similar to the rash seen in patients
receiving EGFR inhibitor drugs. Skin biopsy demonstrated an altered cellular distribution of
EGFR in the epidermis with reduced cell membrane labeling, and in vitro analysis of the mutant
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receptor revealed abrogated EGFR phosphorylation and EGF-stimulated downstream signaling.
Microarray analysis on the patient’s skin highlighted disturbed differentiation/premature terminal
differentiation of keratinocytes and upregulation of several inflammatory/innate immune response
networks. The boy died aged 2.5 years from extensive skin and chest infections as well as
electrolyte imbalance. This case highlights the major mechanism of epithelial dysfunction
following EGFR signaling ablation and illustrates the broader impact of EGFR inhibition on other
tissues.
INTRODUCTION
EGFR signaling represents a key activity in several biologic processes underpinning tissue
development and homeostasis (Jutten and Rouschop, 2014). Thus far, 7 EGFR ligands have
been identified: EGF, transforming growth factor-α, amphiregulin, heparin-binding EGF-
like growth factor, betacellulin, epiregulin, and epigen (Schneider and Wolf, 2009; Nanba et
al., 2013). Interaction between EGFR and these ligands leads to stimulation of numerous
transduction pathways that includes the RAS/RAF/MEK/ERK, PLC-gamma/PKC, PI3K/
AKT, JAK/STAT, and NF-κB cascades (Jost et al., 2000; Silbilia et al., 2007). Acquired
abnormalities of EGFR signaling have been observed in various inflammatory and
malignant diseases (Jost et al., 2000; Gschwind et al., 2004; Dreux et al., 2006; Zhang et al.,
2014). Of note, aberrant EGFR activation is found in many tumor cells, and humanized
neutralizing antibodies and synthetic small compounds against EGFR are in clinical use
today. These drugs may cause skin and hair toxicities, indicating a key role for EGFR in
cutaneous homeostasis (Lacouture, 2006; Liu et al., 2013). These side-effects have been
recapitulated in a mouse model, with evident abnormalities in cutaneous chemokines
associated with early infiltration of macrophages and mast cells and later infiltration of
eosinophils, T cells and neutrophils (Mascia et al., 2013). EGFR mutations in tumors are
typically gain-of-function and located within the tyrosine kinase domain of the protein, but
thus far there are no reports of naturally occurring loss-of-function mutations in humans.
Knockout and transgenic murine models and in vitro studies have demonstrated the essential
role of EGFR in multiple organs (Miettinen et al., 1995; Silbia and Wagner, 1995;
Threadgill et al., 1995; Jost et al., 2000; Schneider et al., 2008), but clinical correlates in
patients are currently lacking. In this study, we used whole-exome sequencing to identify an
inherited loss-of-function mutation in EGFR in an individual with inflammatory skin, lung
and bowel disease.
RESULTS AND DISCUSSION
Clinical presentation with cutaneous erosions and inflammation
We investigated a male infant born to parents of Polish Roma origin who presented to us at
12 months of age with extensive skin inflammation. Initially, there were widespread
erosions affecting his trunk and limbs that had been present since birth (Figure 1a), but
subsequently we observed papules and pustules (Figure 1b). He also had life-long watery
diarrhea and respiratory difficulties. He was born at 34 weeks’ gestation, weighing 1560
grams; the pregnancy had been complicated by polyhydramnios and maternal hypertension.
Clinically, at 12 months his weight was only 5.52kg with evident failure to thrive. His
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inflamed skin was frequently infected with Staphylococcus aureus. He had loss of scalp hair
but long eyelashes (trichomegaly). No nail abnormalities were observed. He had previously
undergone surgery for probable coarctation of the aorta and was noted to be hypertensive.
Other abnormalities included recurrent bronchiolitis and pulmonary infection with
Pseudomonas aeruginosa (requiring tracheostomy and oxygen). Renal ultrasound showed
bilateral renal enlargement but no obstruction. The child had no specific food allergies but
was unable to tolerate solids due to diarrhea and vomiting and severe dehydration. We
observed low albumin, zinc, vitamin A, iron, magnesium, profound hypokalaemia
(persistent), and hypernatraemia - though barium meal showed no evidence of
malabsorption. He preferred to drink water rather than milk and subsequently required total
parenteral nutrition. Blood eosinophil counts were slightly elevated during the first year
(observed levels 0.4-1.0 × 109/l). Total IgE was found to be raised as a neonate (100 IU/l;
range for <1 year 0-15 IU/l) and at 15 months (107 IU/l; range for this age 0-60 IU/l). IgM
was borderline normal/low; IgG and IgA were normal. Venous access lines frequently
became clotted and he developed deep vein thromboses. He died aged 2.5 years as a result
of cutaneous and pulmonary infections and electrolyte imbalance. Further details of the
clinical history can be found in the Supplementary Material.
Skin biopsy reveals acanthosis and intra-epidermal edema
We obtained written informed consent from the subject’s legal guardian with approval from
the St. Thomas’ Hospital Ethics Committee. Elliptical skin biopsies were obtained under
local anesthetic from a non-lesional area on the right thigh of the child (aged 12 months) as
well as the abdomens of healthy control patients undergoing cosmetic (“tummy tuck”)
surgery. The initial clinical diagnosis was a subtype of inherited skin fragility, a
heterogeneous group of disorders known collectively as epidermolysis bullosa (EB) (Fine et
al., 2008). Light microscopy of non-lesional skin revealed mild acanthosis compared to age-
and site-matched control skin, as well as a slight widening between adjacent keratinocytes
(Figure 2a). A few neutrophils were noted within the superficial dermis with some
infiltration of follicular epithelium and folliculitis, although Gram stain for bacteria was
negative. The changes within the epidermis resembled those of a primary inherited
abnormality of desmosomes (Petrof et al., 2012), although transmission electron microscopy
showed intercellular edema from the basal layer to the mid-spinous layer and a slight
decrease in the number of gap junctions but no structural or numerical abnormalities in
hemidesmosome or desmosome cell junctions (Figure 2b). Skin immunolabeling using a
panel of antibodies that target basement membrane and epidermal proteins implicated in
inherited skin fragility disorders (see Supplementary Material for antibody details)
demonstrated a marked reduction in staining intensity for the desmosomal proteins
desmoglein 1 and plakophilin 1, as well as altered labeling patterns for profilaggrin,
involucrin and keratin 10, markers of terminal differential in the epidermis (illustrated in
Supplementary Material). Some of the clinicopathologic features also resembled Netherton
syndrome, an autosomal recessive disorder associated with loss-of-function mutations in a
serine protease inhibitor (SPINK5) that encodes lympho-epithelial Kazal-type related
inhibitor (LEKT1) (Chavavas et al., 2000; Stoll et al., 2001). Immunostaining for LEKTI in
our patient’s skin, however, revealed a slight increase compared to control (illustrated in
Supplementary Material)– in contrast to findings of reduced LEKTI expression that usually
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accompany Netherton syndrome. Taken together, these findings were not in keeping with
any known form of EB, Netherton syndrome or any other recognized inherited or acquired
skin disease.
Whole-exome sequencing reveals a homozygous missense mutation in EGFR
Next, after obtaining approval from the ethics committee and informed consent, we
extracted genomic DNA from peripheral blood samples from the child, other family
members and controls in compliance with the Helsinki Guidelines. Using the patient’s DNA,
whole-exome sequencing was performed on the Illumina HiSeq 2000 (San Diego, CA,
USA). After excluding pathogenic mutations in genes implicated in different forms of EB
(Fine et al., 2008), the exome variant profile was filtered to look for novel homozygous
mutations (based on probable consanguinity). This disclosed 6 possible gene mutations (see
Supplementary Material). Within these genes, EGFR was deemed to be of potential
relevance given that some clinical features (e.g. papulo-pustular skin eruptions, alopecia and
trichomegaly) resembled known side-effects of EGFR inhibitor drugs (Lacouture, 2006).
Immunofluorescence microscopy to assess EGFR expression in the affected infant’s skin
showed a markedly altered staining pattern with loss of the cell peripheral membrane
labeling and a more cytoplasmic or peri-nuclear region distribution, compared to strong cell
membrane localization of EGFR throughout the epidermis, with minimal intracellular
labeling, in control skin (Figure 2c). The non-synonymous substitution identified in exon 11
of EGFR, c.1283G>A, replaces a neutral glycine with a negatively charged aspartic acid
molecule at a highly conserved residue, p.Gly428Asp. The pathogenicity of this missense
mutation was supported by both the ‘Sorts Intolerant From Tolerant’ (SIFT; score 0,
probably damaging) and Polymorphism Phenotyping v2 (polyphen-2; score 1, probably
damaging) programs (Ng and Henikoff, 2003; Adzhubei et al., 2010). The EGFR mutation
was also validated by Sanger sequencing (Figure 2d; primers for EGFR amplification are
given in Supplementary Material) and found to be homozygous in the affected patient,
heterozygous in the mother, and homozygous wild-type sequence in the unaffected older
sibling; DNA from the father was not available. The mutation is located in extracellular
domain III of EGFR (Figure 2e), in contrast to the tyrosine kinase domain mutations
commonly found in tumors (Kumar et al., 2008). The region surrounding the mutation has
been postulated to be involved in intra-molecular interactions that promote dimerization of
EGFR and receptor activation (Ogiso et al., 2002; Dawson et al., 2005). We were unable to
find the observed mutation in the dbSNP database, the 1000 Genomes database, the 13,005
exomes in the Exome Variant Server or in 900 unrelated European in-house control exomes.
Aberrant cutaneous expression of genes germane to keratinocyte differentiation,
inflammatory response and innate immunity
Microarray data have been deposited in the Gene Expression Omnibus repository; accession
number GSE54162. Comparison of the affected infant’s skin with healthy control skin
identified 2-fold or greater differential expression for 2,157 gene transcripts: 1004 up-
regulated and 1153 down-regulated. These genes did not include EGFR, which was
insignificantly up-regulated in the patient’s skin (fold change=1.36; p=0.012). Evaluation of
the changes in gene expression by functional enrichment analysis identified a multitude of
enriched gene ontology (GO) pathways, processes, networks and disease-associated
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transcripts germane to EGFR signaling (see Supplementary Materials for tabulated results).
The top 3 up-regulated GO processes were linked to known EGFR functionality:
keratinocyte differentiation, keratinization and epidermis development (involving genes
such as transglutaminases, small proline rich genes, S100 genes, involucrin and late
cornified envelope genes). Reports have also indicated a role for EGFR in regulating skin
inflammation and cutaneous defence (Lichtenberger et al., 2013; Mascia et al., 2013). Thus,
innate inflammatory response gene components (specifically PLA2, NF-κB, and JNK1)
were among the most significantly up-regulated GO networks. Notably, CCL2 expression
was increased 2.2 fold, in keeping with reported findings in mouse models lacking
epidermal Egfr expression (Lichtenberger et al., 2013). Additionally, regulation of
epithelial-to-mesenchymal transition and angiogenesis, processes known to be controled by
EGFR activation (Perrotte et al., 1999; Avraham and Yarden, 2011), were identified as
significantly down-regulated GO pathways and processes, respectively. Of note, there was
also down-regulation of transcripts that are normally increased in tumors which show gain-
of-function mutations in EGFR (e.g. non-small cell lung cancer, colorectal cancer, and
glioblastoma).
Mutant EGFR at the plasma membrane is highly unstable and more susceptible to
constitutive endocytosis
To determine whether the mutation p.Gly428Asp in EGFR was responsible for
mislocalization of EGFR in the affected infant, we generated DNA constructs containing
mutant or wild-type EGFR sequence linked to green fluorescent protein (GFP) and
expressed these constructs in MCF7 cells that express low endogenous EGFR and analyzed
EGF-dependent localization of EGFR using confocal microscopy. Under normal growth
conditions, the mutant EGFR construct localized diffusely throughout the cytoplasm of the
cell in contrast to the wild-type construct, which was present mostly on the plasma
membrane (Figure 3a). EGF stimulation resulted in robust translocation of wild-type EGFR
to the plasma membrane within 10 minutes of EGF treatment (Figure 3b). Conversely, the
mutant EGFR remained in the cytoplasm following EGF stimulation with no clear
recruitment to the plasma membrane (Figure 3b), suggesting this mutation prevents or
diminishes EGFR membrane localization, supporting the immunostaining findings in patient
skin (Figure 2c).
EGFR membrane localization is regulated through a balance of endocytosis under the
control of a number of intracellular signaling pathways that converge on the large GTPase
dynamin (Lee et al., 2006). To examine whether the lack of mutant EGFR localization to the
cell membrane was due to defective endocytic traffic, MCF-7 cells expressing either wild-
type or mutant EGFR were treated with an inhibitor of dynamin-mediated endocytosis,
Dynasore (Macia et al., 2006). Receptor localization was then examined by confocal
microscopy. In the absence of ligand, membrane localization of both wild-type and mutant
EGFR increased after treatment with Dynasore (Figure 3c). Similar results were observed in
a normal human keratinocyte cell line expressing wild-type or mutant EGFR (see
Supplementary Material). Immunostaining of MCF-7 cells expressing wild-type or mutant
EGFR was performed using an antibody against the extracellular domain of EGFR to
quantify membrane localization. Pearson’s correlation coefficient analysis to quantify the
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co-localization between wild-type or mutant EGFR with the antibody staining demonstrated
that for both constructs the EGFR membrane localization increased significantly following
Dynasore treatment (Figure 3c) but not following treatment with the chemical chaperone 4-
PBA (data not shown). These data demonstrate that the mutant EGFR is able to undergo
recycling to the plasma membrane but that it can only be retained at the membrane upon
blockade of endocytic signaling. This suggests that the mutation p.Gly428Asp renders
EGFR at the plasma membrane highly unstable and thus more susceptible to constitutive
endocytosis.
Loss of downstream Akt and ERK signaling associated with mutant EGFR
Following EGF binding, EGFR undergoes rapid autophosphorylation and activation at a
number of residues within the cytoplasmic domain of the receptor. These changes result in
recruitment of a host of initiators and scaffolds of signaling leading to activation of MAP
kinase family members including ERK (p44/42) and Akt (Avraham and Yarden, 2011). We
therefore assessed the effect of the mutation p.Gly428Asp on EGF dependent
phosphorylation of EGFR and downstream signaling. EGF-dependent ERK and Akt
activation were assessed in untransfected MCF-7 cells or those expressing wild-type or
mutant EGFR. EGF-stimulated activation of EGFR (monitored by a phospho-specific
antibody) was robust in the cells expressing wild-type EGFR, but was undetectable in the
mutant EGFR-expressing cells above levels seen in untransfected controls (Figure 4a).
Similarly, neither Akt nor ERK activation was detected following ligand binding in mutant
EGFR-expressing cells, in contrast to cells expressing wild-type EGFR which showed
robust EGF-stimulated EGFR, ERK and Akt phosphorylation (Figure 4a). We observed
similar results in parallel experiments in another cell line (CHO-K1 cells) (see
Supplementary Material for data).
The suppression of EGFR-dependent activation and downstream signaling observed
suggests that the EGFR mutation p.Gly428Asp results in loss-of-function as well as loss of
plasma membrane localization. One of the primary functions of EGFR signaling following
EGF binding is to promote cell proliferation (Jost et al., 2000). To determine whether the
loss of EGF-dependent signaling in p.Gly428Asp mutant EGFR-expressing cells results in
functional defects, proliferation was analyzed in CHO-K1 cells expressing the wild-type or
mutant EGFR constructs. EGF and serum-stimulated proliferation was induced in CHO-K1
cells expressing wild-type EGFR, but no induction of cell growth was detected in cells
expressing the mutant EGFR (Figure 4b). Indeed, there was a negative growth rate of the
mutant EGFR-expressing cells, consistent with other work showing inhibition of EGFR
signaling induces apoptosis in keratinocytes (Figure 4c) (Rodeck et al., 1997).
Clinicopathologic overlap with patients harboring mutations in ADAM17
The exact mechanism by which the missense mutation p.Gly428Asp leads to loss of EGFR
function is unclear. Mutagenesis of the adjacent amino acid (p.Arg429Glu) was previously
found to prevent EGFR homo-dimerization through disruption of an interface between
domains II and III of the protein (Dawson et al., 2005). However, altered homo-dimerization
would not provide a sufficient explanation for the pathology as both monomeric EGFR and
the p.Arg429Glu mutant were present at the plasma membrane (Ogiso et al., 2002). In our
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experiments, we found that inhibition of endocytosis promoted levels of mutant EGFR at the
cell surface. We hypothesize that the mutant receptor is unstable and rapidly undergoes
internalization from the plasma membrane, perhaps implicating altered intracellular protein
binding and subsequent aberrant tethering within membrane microdomains.
Functionally, failure of EGFR to correctly localize to cell membrane is expected to reduce
ligand binding. In healthy people, several ligands require proteolytic cleavage to become
capable of binding to EGFR – this ectodomain shedding is induced by at least 5 different
metalloprotease enzymes, including ADAM17 (Blobel, 2005) – mutations in which may
underlie an inflammatory skin and bowel disease that has overlap with the clinical features
present in our patient (Blaydon et al., 2011). We hypothesize that the lack of EGFR
localization at the cell membrane in our patient has some similarity at a signaling level to
that which occurs in the ADAM17-deficient patients, i.e. a common failure of EGFR-ligand
interaction and altered downstream signal transduction.
Clinicopathologic similarities with mouse models of EGFR impairment
The clinical manifestations of the mutation p.Gly428Asp in terms of loss of EGFR function
show some similarities with the phenotype of Egfr knockout or transgenic mice (Miettinen
et al., 1995; Silbia and Wagner, 1995; Threadgill et al., 1995; Schneider et al., 2008).
Although the phenotype of Egfr-deficient mice depends on the strain of the mice (several are
embryonic lethal), the abnormalities in the skin, lung and bowel in surviving mice are
similar to many of the clinical manifestations in our patient. In the epidermis, some
knockout mice show an initially thin skin that then becomes thicker but with defective
barrier function (Miettinen et al., 1995). Lack of Egfr in mice also affects hair growth, with
wavy or reduced hair growth; EGFR is essential for normal hair follicle progression through
the anagen, catagen, and telogen phases of the hair growth cycle (Hansen et al., 1997;
Schneider et al., 2008). EGFR initiates hair growth and hair follicle organization, and EGFR
inhibition leads to inflammation, follicular necrosis and alopecia, as well as slow hair
growth with brittle hairs, as observed in our patient (Hansen et al., 1997; Schneider et al.,
2008). Egfr-deficient mouse lungs show condensed collapsed alveoli with a lack of
surfactant leading to respiratory difficulty that has been likened to human neonatal
respiratory distress syndrome (Miettinen et al., 1995). In murine bowel lacking Egfr, there
are fewer, shorter intestinal villi and reduced proliferation of jejunal enterocytes, leading to
fluid loss (Miettinen et al., 1995). Other abnormalities noted in the mice that show
phenotypic similarities to our patient have included cystic dilatation of the collecting ducts
in the kidneys (indicating that EGFR is vital for the differentiation of structures derived
from the ureteric bud), aortic narrowing and a thrombotic tendency (Miettinen et al., 1995).
In addition, there are similarities in the phenotype of transgenic Egfr-and Adam17 mice, thus
supporting the clinical overlap in humans with germline autosomal recessive mutations in
EGFR or ADAM17 (Peschon et al., 1998).
Clinical resemblance to the side-effects of EGFR inhibitor medications
The clinical manifestations in the child homozygous for p.Gly428Asp in EGFR also show
some resemblance to the side-effect profile in individuals taking EGFR inhibitors. The side-
effects of these drugs include a distinctive acne-like rash with pustules, dry skin, alopecia,
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trichomegaly, as well as mucositis, diarrhea, and, in rare instances, interstitial lung disease
(Inoue et al., 2013; Lacouture, 2006). All these clinical features were evident to some degree
in our patient. Nevertheless, although skin papules and pustules developed during disease
progression in our case, the early skin changes mostly consisted of erosions (which led to
the erroneous initial clinical diagnosis of EB). EGFR signaling is known to be involved in
the re-epithelialization phase of wound healing (Repertinger et al., 2004; Pastore et al.,
2008), as well as the proliferation of keratinocyte stem cells (Jensen et al., 2009), and we
hypothesize that the missense mutation in our patient impeded these processes and was the
primary cause of the erosive skin changes, with bacterial super-infection being a secondary
contributing factor. The transcriptomic data from our patient illustrate the consequences of
impaired EGFR signaling. The results (albeit based on RNA extracted from non-inflamed
skin) reveal enhanced pro-inflammatory activation and disturbed differentiation/premature
terminal differentiation of keratinocytes as key pathogenic mechanisms, thereby
demonstrating a similar profile to that associated with the papulopustular rash associated
with EGFR inhibitory drugs (Lacouture, 2006; Lichtenberger et al., 2013; Mascia et al.,
2013). Notably, several inflammatory/innate response networks were significantly up-
regulated, including NF-κB.
In conclusion, the EGFR network is one of the most influential and intricate signaling
systems in biology. We believe the protean features in our patient offer clinical insight into
the critical and diverse roles of EGFR, supporting many of the putative functions that have
been ascribed to the receptor via murine models and in vitro studies. This case highlights the
major mechanism of epithelial dysfunction following EGFR signaling ablation and
illustrates the broader impact of EGFR inhibition on other tissues that might be under-
appreciated in the context of concurrent malignancy in patients receiving EGFR inhibitor
medications.
MATERIALS AND METHODS
Transmission electron microscopy
Small pieces of skin (<2mm3) were prepared for transmission electron microscopy, as
described in the Supplementary Material.
Immunofluorescence microscopy
A skin biopsy from the affected infant and control skin were collected in Michel’s medium.
The methods for immunofluorescence microscopy and primary antibodies used are listed in
the Supplementary Material.
Whole-exome sequencing
Initially, 3 μg of genomic DNA was sheared with focused acoustic technology (Covaris,
Woburn, MA, USA) to yield a mean fragment size of 150bp. Fragments ends were repaired
and sequencing adaptors ligated. Biotinylated 120bp RNA probes (Agilent, Santa Clara, CA,
USA), designed against the coding regions of the genome were hybridized with the
sequence library for 24 hours. DNA bound to RNA probes was retained using streptavidin-
coated magnetic beads; unbound DNA was washed off. The exome-enriched pool of DNA
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was eluted and amplified with a low-cycle PCR. The DNA fragments were then sequenced
with 100 bp paired-end reads. Novoalign (Novocraft technologies, Selangor, Malaysia) was
used to align reads to the reference genome (hg19, National Center for Biotechnology
Information build 37). With over 7.0 Gb of sequence generated, more than 90% of coding
bases of the GENCODE-defined exome were represented by at least 20 reads (see
Supplementary Material).
Sanger sequencing
We sequenced the exon and intron/exon boundaries of all 28 exons of EGFR, including the
mutation present in exon 11, in the infant, mother, unaffected older brother and 3 controls.
Each exon was amplified by PCR using AmpliTaq Gold® 360 Master Mix (Applied
Biosystems, Foster City, CA, USA) and the primers listed in the Supplementary Material.
Whole-genome expression microarray analysis
Whole-genome expression microarray analysis was performed using RNA extracted from
skin biopsies sampled from the affected child as well as 4 pooled, healthy controls. RNA
extraction from cutaneous biopsies was performed using the Ambion mirVana miRNA
Isolation kit (Invitrogen, Paisley, UK) according to the manufacturer’s instructions. RNA
was amplified using the Illumina TotalPrep RNA Amplification Kit (Illumina, San Diego,
CA, USA) and subsequent gene expression profiling was performed using the Illumina array
HumanHT-12 v4.0 Expression BeadChip kit according to the manufacturer’s instructions
(Illumina). Gene expression data were then analyzed using GenomeStudio software
(Illumina). Control samples were pooled and compared to the affected individual.
Mutant construct transfection
Mutant complementary cDNA mimicking the mutation of the infant (c.1283G>A) was
generated with green fluorescent protein (GFP) tagged to the C-terminus of EGFR. Wild
type EGFR1-GFP was a gift from Dr Andrew Reynolds (Institute for Cancer Research,
London, UK). The mutant construct, p.Gly428Asp EGFR-GFP was generated using a site-
directed mutagenesis kit (Stratagene, La Jolla, CA, USA) as per the manufacturer’s
instructions using the following mutagenesis primer: 5′
GAGAACCTAGAAATCATACGCGACAGGACCAAGCAACATGGT-3′. The mutation in
the plasmid was verified by sequencing. Transfection was carried out using Fugene (Roche
Applied Science, Penzberg, Germany) or Lipofectamine (Invitrogen) reagents according to
manufacturer’s instructions.
Confocal microscopy
For confocal microscopy, cultured MCF-7 human breast adenocarcinoma cells were
transfected with wild-type EGFR-GFP or p.Gly428Asp EGFR-GFP washed with PBS, fixed
with 4% paraformaldehyde (PFA) in PBS for 10 mins and then permeabilized with 0.2%
TritonX-100 for 10 mins. For EGF stimulation experiments, cells were incubated in serum-
free media (Opti-MEM®; Gibco Life Technologies, Carlsbad, CA, USA) for 16h prior to
stimulation with 100 ng/ml EGF for the indicated times. For endocytosis inhibition
experiments, cells were treated for 1 hour with 10 μM Dynasore (Millipore, Billerica, MA,
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USA) or equivalent volume of dimethyl sulfoxide (DMSO) as a control prior to fixation.
Where appropriate, cells were incubated with a primary antibody directed against the
extracellular domain of EGFR for 2h followed by the relevant secondary antibodies
conjugated to Alexafluor-568 and Phalloidin conjugated to Alexafluor 568 or 633 for 1h at
room temperature.
Western blotting
Thirty-thousand MCF-7 or CHO cells per condition were cultured in either Dulbecco‘s
modification of Eagle‘s medium (DMEM) alone or DMEM containing 10% fetal calf serum
(10% FCS) and transfected with wild-type EGFR-GFP or p.Gly428Asp EGFR-GFP; 36h
later, the cells were starved for 16h with Opti-MEM® (Gibco Life Technologies) before
treatment with 100 ng/ml EGF for the appropriate times. Cells were then lysed in sample
buffer containing 2-mercaptoethanol at room temperature. Lysates were immediately
subjected to SDS-PAGE and blotted using nitrocellulose membrane. Blots were blocked and
probed using p-ERK, ERK, p-Akt, Akt, p-EGFR and EGFR antibodies (Cell Signaling
Technology, Beverly, MA, USA), as well as HSC-70 antibodies (Santa Cruz Biotechnology,
Dallas, Texas, USA), using 3% milk/PBS-0.2%tween or 5%BSA/TBS-0.1%tween.
Growth assessment rates
Ten-thousand CHO cells per condition were cultured in DMEM containing 10% FCS for
24h before transfection with GFP alone, wild-type EGFR-GFP or p.Gly428Asp EGFR-GFP.
Twenty-four hours later, the media was replaced with normal growth media (10% FCS),
growth media minus FCS or growth media minus FCS supplemented with 100 ng/ml EGF.
Cells were then either Hoechst treated and fixed immediately with 4% PFA or were fixed
24h later. Phase and Hoechst images of 5 fields of view per condition were taken using an
Olympus IX71 widefield microscope with a 4× 0.13 NA air objective (Olympus, Tokyo,
Japan). Images were then analyzed for total number of cells as well as GFP expressing cells.
The number of GFP expressing cells was then normalized using the total number of cells per
field of view and presented either as the average number of GFP expressing cells per
condition or the growth rate per condition.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clinical features of the patient demonstrating inflammation, erosions, papules and
pustules
(a) At 12 months of age the infant has extensive erosions and markedly reduced scalp hair
and eyebrows. He is also receiving total parenteral nutrition. (b) At 22 months there is a
confluent papular eruption, particularly on the limbs, with numerous pustules. Consent to
publish these photographs was obtained from the infant’s mother.
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Figure 2. The homozygous mutation p.Gly428Asp results in acanthosis, intra-epidermal edema,
and loss of keratinocyte cell membrane labeling for EGFR
(a) Semithin section of patient skin from the thigh reveals acanthosis and hyperkeratosis
compared to age and site-matched control skin (scale bars = 50 μm). (b) Ultrastructurally,
there is widening of spaces between adjacent keratinocytes in the lower epidermis (asterisks;
scale bar = 2 μm). (c) Immunostaining for EGFR in patient epidermis shows loss of
keratinocyte membrane staining compared to control skin (scale bars = 50 μm). (d) Sanger
sequencing reveals a homozygous missense mutation in EGFR. (e) Schematic representation
of the functional domains and encoding exons and the site of the pathogenic mutation in this
patient. TM = transmembranous domain.
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Figure 3. The mutation in EGFR renders the receptor unstable and susceptible to endocytosis
(a) Confocal microscopy was performed using GFP-tagged constructs of wild-type or
mutant EGFR (green) and F-actin (red) in MCF-7 cells under normal growth conditions. (b)
Images were then taken following stimulation of the cells with EGF at specified time points
to assess the localization of EGFR within the cell cytoplasm or at the cell membrane. (c)
Confocal microscope images were also taken for wild-type and mutant EGFR-GFP
constructs (green) in cells stained for surface EGFR (red) in DMSO (dimethyl sulfoxide)
control or Dynasore-treated cells (to inhibit endocytosis). The colocalization between EGFR
antibody staining and either wild-type or mutant EGFR-GFP constructs was then quantified
in DMSO control or Dynasore-treated cells using Pearson’s correlation coefficient (Panel D
lower). * p<0.001 vs WT-EGFR; scale bars = 10μm.
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Figure 4. The mutation in EGFR reduces signal transduction and cell proliferation
(a) Western blotting was performed for p-EGFR, EGFR, p-ERK, ERK, p-Akt and Akt on
lysates from untransfected (U), wild-type EGFR (WT) or mutant EGFR (MUT) transfected
MCF-7 cells after EGF stimulation for the indicated times. MCF-7 cells express very low
endogenous EGFR and therefore EGFR is undetectable in UT cells. Arrows indicate
phospho and total EGFR species in top and second row blots respectively. Note the higher
molecular weight species of EGFR in the WT samples in the second row blot are
phosphorylated receptor and directly correlate with phosphorylated EGFR as detected in the
top row blot. (b) Cell proliferation was quantified in CHO-K1 cells transfected with GFP,
wild-type EGFR-GFP or mutant EGFR-GFP in starved (−), normal growth (10% fetal calf
serum) or EGF-stimulated (EGF) conditions. (c) GFP-positive cells were counted and
normalized against total cell number, and the cell growth rate was then calculated from these
data.
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